S

    Scholar Rock Holding Corp (SRRK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $56.80
    -1.00 (-1.73%)

    Market Cap: $6.92B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(15/34)
    Avg Surprise
    -90.65%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.83
    Range$-0.94 - $-0.66
    12 analysts
    EPS Revisions
    3
    0
    7d
    3
    1
    30d
    EPS Estimate Drift
    90d ago$-0.85-3.1%
    60d ago$-0.85-3.1%
    30d ago$-0.85-3.1%
    7d ago$-0.83+0.0%
    Current$-0.83
    Revenue Consensus
    $70000
    Range$0 - $1M
    15 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.67
    Range$-1.10 - $0.29
    12 analysts
    Revenue Consensus
    $6M
    Range$2M - $10M
    16 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.67---
    Sep 26EST
    		-$-0.83---
    Jun 26
    Reported Aug 6
    		$-0.84$-0.84+0.00%Beat+14.3%
    Mar 26
    Reported May 7
    		$-0.83$-0.78-6.41%Miss-23.9%
    Dec 25
    Reported Mar 3
    		$-0.88$-0.90+2.04%Beat-44.3%
    Sep 25
    Reported Nov 14
    		$-0.90$-0.84-7.14%Miss-36.4%
    Jun 25
    Reported Aug 6
    		$-0.98$-0.67-46.27%Miss-63.3%
    Mar 25
    Reported May 14
    		$-0.67$-0.71+5.63%Beat-13.6%
    Dec 24
    Reported Feb 27
    		$-0.61$-0.63+2.99%Beat-22.0%
    Sep 24
    Reported Nov 12
    		$-0.66$-0.59-11.86%Miss-24.5%
    Jun 24
    Reported Aug 8
    		$-0.60$-0.59-1.69%Miss-27.7%
    Mar 24
    Reported May 7
    		$-0.59$-0.51-15.69%Miss-20.4%
    Dec 23
    Reported Mar 19
    		$-0.50$-0.49-2.04%Miss-8.7%
    Sep 23
    Reported Nov 7
    		$-0.53$-0.51-3.92%Miss+3.6%
    Jun 23
    Reported Aug 9
    		$-0.47$-0.55+14.55%Beat+55.7%
    Mar 23
    Reported May 9
    		$-0.49$-0.52+5.77%Beat-133.3%
    Dec 22
    Reported Mar 7
    		$-0.46$-0.57+19.30%Beat+52.6%
    Sep 22
    Reported Nov 14
    		$-0.55$-0.64+14.06%Beat+46.1%
    Jun 22
    Reported Aug 8
    		$-1.06$-1.01-4.95%Miss-26.2%
    Mar 22
    Reported May 16
    		$-0.21N/A+66.13%Beat+72.4%
    Dec 21
    Reported Mar 7
    		$-0.97$-1.00+3.00%Beat-22.8%
    Sep 21
    Reported Nov 9
    		$-1.02$-0.76-34.21%Miss-29.1%
    Jun 21
    Reported Aug 10
    		$-0.84$-0.73-15.07%Miss-29.2%
    Mar 21
    Reported May 13
    		$-0.76$-0.65-16.92%Miss-31.0%
    Dec 20
    Reported Mar 9
    		$-0.79$-0.63-25.40%Miss-102.6%
    Sep 20
    Reported Nov 9
    		$-0.79$-0.50-58.00%Miss-43.6%
    Jun 20
    Reported Aug 7
    		$-0.65$-0.46-41.30%Miss-35.4%
    Mar 20
    Reported May 7
    		$-0.58$-0.02-2800.00%Miss-38.1%
    Dec 19
    Reported Mar 12
    		$-0.39$-0.53+26.42%Beat+9.3%
    Sep 19
    Reported Nov 12
    		$-0.55$-0.41-34.15%Miss-25.0%
    Jun 19
    Reported Aug 14
    		$-0.48$-0.31-54.84%Miss+17.2%
    Mar 19
    Reported May 14
    		$-0.42$-0.50+16.00%Beat+58.8%
    Dec 18
    Reported Mar 18
    		$-0.43$-0.45+4.44%Beat-126.3%
    Sep 18
    Reported Nov 8
    		$-0.44$-0.56+21.43%Beat-
    Jun 18
    Reported Aug 8
    		$-0.58$-0.58+0.00%Beat-
    Mar 18
    Reported May 24
    		$-1.02$-0.50-104.00%Miss-
    Mar 17
    Reported Jun 29
    		$-0.19$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-16.46EV/EBITDA-2.08x
    Price/FCF-24.98xFCF Yield-4.00%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-167.80%ROIC-71.59%
    Financial Health
    Debt/Equity0.77xInterest CoverageN/A
    Current Ratio7.02xQuick Ratio7.02x
    Trading Statistics
    Beta0.67Avg Volume1.07M
    52-Week High$61.7652-Week Low$27.07

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$57.33
    SMA 20$54.50
    SMA 50$53.10
    SMA 200$47.28
    EMA 10$56.95
    EMA 20$55.26
    EMA 50$52.85
    EMA 200$47.18

    MACD

    Line: 1.98Signal: 1.63Hist: 0.35

    ADX

    ADX: 33.3+DI: 28.4-DI: 15.5

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down20.0
    PSAR$61.76

    Bollinger Bands

    Upper Band$61.40
    Lower Band$47.60
    %B Position2532%(Upper)
    Band Width0.67

    RSI (14-Day)

    Neutral
    57.3

    Momentum Oscillators

    Stoch %K63.8
    Stoch %D74.1
    Williams %R-48.3
    ROC (10d)9.1%
    Momentum4.75
    CCI (20d)58.1
    MFI (14d)66.5

    Volatility Measures

    ATR (14d)$2.36(4.2%)
    StdDev (20d)3.45
    Hist Vol49.9%(High)

    Volume Flow

    VWAP$56.84
    OBV20.1M
    AD Line29.3M
    CMF (20d)0.151

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.9x
    VWMA (20d)$54.98

    Pivot Points

    R3$61.14
    R2$60.22
    R1$59.01
    Pivot Point$58.09
    S1$56.88
    S2$55.96
    S3$54.75

    Advanced Oscillators

    TSI22.78
    Ultimate Osc55.7
    KST108.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$11.66M$0
    Cost of Revenue$0$0$425,000$0$0$0$395,000$0$0$0$672,000$0
    Gross Profit$0$0$-425,000$0$0$0$-395,000$0$0$0$-672,000$0
    Operating Expenses$108.90M$102.02M$91.90M$103.55M$112.11M$77.09M$69.36M$64.78M$59.50M$58.42M$48.03M$43.67M
    R&D$58.23M$51.81M$46.88M$50.49M$62.40M$48.68M$50.36M$48.72M$42.37M$43.09M$34.96M$30.34M
    SG&A$50.67M$50.20M$45.02M$53.06M$49.71M$28.41M$18.99M$16.06M$17.13M$15.32M$13.07M$13.34M
    Operating Income$-108,901,000$-102,016,000$-91,896,000$-103,550,000$-112,109,000$-77,090,000$-69,357,000$-64,780,000$-59,498,000$-58,419,000$-48,032,000$-43,672,000
    Interest Income$4.09M$2.94M$0$2.73M$3.41M$4.23M$0$2.08M$2.72M$0$0$0
    Interest Expense$4.52M$2.30M$0$1.33M$1.21M$1.82M$0$1.74M$1.72M$0$0$0
    Income Before Tax$-109,896,000$-102,173,000$-88,598,000$-102,220,000$-110,031,000$-74,723,000$-64,888,000$-64,479,000$-58,508,000$-58,419,000$-48,032,000$-43,672,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-109,896,000$-105,510,000$-90,965,000$-102,220,000$-110,031,000$-74,723,000$-66,454,000$-64,479,000$-58,508,000$-56,853,000$-46,126,000$-42,359,000
    EBITDA$-109,201,000$-102,606,000$-91,571,000$-103,828,000$-111,904,000$-76,957,000$-70,261,000$-65,010,000$-60,273,000$-59,663,000$-49,104,000$-48,418,000
    EBIT$-109,471,000$-102,806,000$-91,896,000$-103,619,000$-112,236,000$-77,134,000$-69,357,000$-64,818,000$-59,512,000$-58,419,000$-48,032,000$-43,672,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SRRK

    News

    Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK

    Bank of New York Mellon Corp has acquired 365,218 shares of Scholar Rock Holding Corporation (NASDAQ:SRRK), valued at approximately $20.1 million, establishing a 0.30% stake in the company. Institutional investors now collectively own 91.08% of Scholar Rock, which has a consensus "Buy" rating and an average price target of $58.77 from Wall Street analysts. The clinical-stage biotech recently reported quarterly EPS of -$0.84, aligning with analyst expectations, and its stock opened near its 52-week high at $57.80.

    MarketBeat•8/31/26•
    Bullish

    Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD

    Scholar Rock Holding Corp (SRRK) reached a 52-week high of $58.52, with shares currently trading just 1% below this peak, reflecting a 59% total return over the past year and a 74.02% 1-year change. Despite this, InvestingPro data suggests the stock is overvalued relative to its Fair Value estimate. Recent news includes a narrower-than-expected Q2 loss and progress on its lead drug apitegromab, with analysts reiterating Buy/Outperform ratings.

    Investing.com•8/24/26•
    Bullish

    BMO reiterates Scholar Rock stock rating on BLA site change

    BMO Capital reiterated an Outperform rating and $76.00 price target on Scholar Rock (NASDAQ:SRRK) after the company removed the Catalent facility from its apitegromab BLA application. BMO believes this removal is unlikely to surprise investors and that FDA approval timelines remain on track for a decision by September 30. Despite five analysts revising earnings upwards, InvestingPro's Fair Value analysis suggests the stock might be overvalued.

    Investing.com•8/24/26•
    Bullish

    Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?

    Scholar Rock (SRRK) shares rose 8.5% after the company announced de-risking moves for its drug apitegromab's global filing pathway. These include removing a contract manufacturer from the U.S. BLA, planning a resubmission in Europe with an alternate facility, and gaining Japanese regulatory alignment for filing without local trials. This significantly reduces operational risk for the global rollout of apitegromab and clarifies the path to key markets, with analysts forecasting substantial revenue and earnings growth by 2029.

    Sahm•8/24/26•
    Somewhat-Bullish

    Scholar Rock removes Catalent facility from SMA drug application

    Scholar Rock has removed Catalent Indiana LLC as a commercial fill-finish facility from its Biologics License Application for spinal muscular atrophy treatment in the U.S. The company made this change following the FDA's "Official Action Indicated" classification of Catalent Indiana's April 2026 inspection. Scholar Rock expects an FDA decision by September 30, 2026, and plans to resubmit its European application with an alternate, U.S.-based facility.

    Investing.com•8/22/26•
    Somewhat-Bullish

    Frequently Asked Questions About SRRK

    Does SRRK pay dividends?
    Scholar Rock Holding Corp (SRRK) does not currently pay a regular dividend.
    What is SRRK's market cap?
    Scholar Rock Holding Corp (SRRK) has a market capitalization of $6.92B with a current stock price of $56.80.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In